8-K
filed November 3, 2022, 7:59 PM ET
ticker LUNG
CIK 0001127537
earnings
confidence high
sentiment negative
materiality 0.75
Pulmonx Q3 revenue $13.5M, cuts FY guidance to $51.5-52.5M; extends credit line to 2027
Pulmonx Corp
2022-Q3 EPS reported
-$1.21
revenue$38,237,000
- Q3 revenue $13.5M (+2% YoY, +7% constant currency); US $8.4M (+22%), intl $5.1M (-20%).
- Net loss $14.2M ($0.38/sh) vs $10.2M ($0.28) in Q3 2021; gross margin 75% vs 73%.
- FY2022 revenue guidance cut to $51.5-52.5M from $55-60M; opex guidance lowered to $98-100M.
- Extended loan with CIBC: maturity to Oct 2027, new $20M tranche, 24-month interest-only period.
- Japan MHLW agreed to approve Zephyr Valves; AeriSeal data may expand treatable patient pool.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Pulmonx Corp reported third quarter ended September 30, 2022 results: revenue 13.5 million.
- Period
- third quarter ended September 30, 2022
- Revenue
- 13.5 million
- Result
- reported results
Exact text from the filing
invasive treatments for lung disease, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights • Achieved worldwide revenue of $13.5 million in the third quarter of 2022, a 2% increase over the same period last year and an increase of 7% on a constant currency basis, driven by U.S. revenue of $8.4 million representing
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Pulmonx Corp reported full year 2022 results: revenue 51.5 million to 52.5 million. Guidance lowered.
- Period
- full year 2022
- Revenue
- 51.5 million to 52.5 million
- Guidance
- lowered
- Result
- guidance update
Exact text from the filing
Pulmonx is updating its full year 2022 revenue guidance to be in the range of $51.5 million to $52.5 million, as compared to previously communicated guidance of $55 million to $60 million.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Pulmonx Corp amended Third Amendment to Amended and Restated Loan and Security Agreement with Canadian Imperial Bank of Commerce valued at $20,000,000 (effective 2022-10-31).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Canadian Imperial Bank of Commerce
- Value
- $20,000,000
- Effective
- 2022-10-31
Exact text from the filing
On October 31, 2022, the Company executed a Third Amendment to Amended and Restated Loan and Security Agreement (the “Third Amendment”) with Canadian Imperial Bank of Commerce (“CIBC”), which amended certain provisions of the Company’s existing Amended and Restated Loan and Security Agreement, dated as of March 29, 2021
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.